March 30, 2026 Sweden
BioStock article following negative interim Phase 3 readout
Diamyd Medical’s CEO Ulf Hannelius and board member, Professor Mark Atkinson, comment on the negative interim readout from the ongoing Phase 3 study DIAGNODE-3, announced on March 27, 2026.
Read the article here
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.